ID

42346

Description

Standard Data Tabulation Model (SDTM) by the Clinical Data Interchange Standards Consortium (CDISC) Based on SDTM v1.7 and the implementation guide SDTMIG v3.3 (for human clinical trials). Quote from https://www.cdisc.org/standards/foundational/sdtmig: "Where the SDTM provides a standard model for organizing and formatting data for human and animal studies, the SDTMIG is intended to guide the organization, structure, and format of standard clinical trial tabulation datasets. It was developed to support data submitted to a regulatory authority, such as the US Food and Drug Administration (FDA), but is not restricted to use in regulated submissions. SDTM is one of the required standards that sponsors must use as specified in the FDA’s Data Standards Catalog (see section II.C) for NDA, ANDA, and certain BLA submissions effective December 2016. For more information, please visit the Guidance on Standardized Data." Domains and Items from other implementation guides (e.g. SDTM-PGx, SDTM-MD) are not included. Please refer to CDISC for information on the implementation of SDTM and associated CDISC standards, do not rely solely on this adaption of CDISC standards. Codelists from the SDTM Terminology included as far as possible in this general version of SDTM (e.g. in the Findings About Domain they are not included, as they depend on the test/result/domain, they are associated with, e.g. COPD Findings About, Cardiovascular Findings About, ...; other test-specific codelists from other domains). Included are the complete codelists referenced in SDTM v1.7 or SDTMIG v3.3, they may need to be constrained depending on the domain or the specific use case. Codelists taken from NCI page https://www.cancer.gov/research/resources/terminology/cdisc in November 2019. CDISC Intellectual Property Policy Version 1.1 (August 15th 2014) Purpose: In its role of leading the development of standards, CDISC must protect those standards to ensure that, to the extent practicable, they remain neutral, open, compensation (royalty)-free, and without encumbering ties to prior intellectual property. This Intellectual Property Policy (“Policy”) is designed to facilitate the activities of CDISC in promotion of such open Standards, to maximize the adoption of such Standards by protecting against the ownership of such Standards by one party and to protect the legitimate intellectual property rights of Contributors.This Policy ensures that CDISC is in accordance with its Bylaws, other Policies and basic Principles.For more information on CDISC, its Bylaws, Strategic Plan, other Policies and basic Principles, please see the CDISC website at www.cdisc.org. Definitions: 2.1“Affiliate” means any entity that directly or indirectly controls, is controlled by, or is under common control with, another entity, so long as such control exists. “Control” means direct or indirect beneficial ownership of or the right to exercise (a) more than fifty percent (50%) of the voting stock or equity in an entity; or (b) more than fifty percent (50%) of the relevant ownership interest or decision-making authority representing the right to make the decisions for the subject entity in the event that there is no voting stock or equity. In the event such control ceases to exist, such Affiliate will be deemed to have withdrawn as a Member, pursuant to the terms set forth in the withdrawal provisions in Section 8. 2.2“CDISC Group” means any CDISC “Working Team,” “Support Team,” “Task Force,” technical working group, or sub-group of a CDISC team or group. 2.3“Contribution” means any material, suggestion, or other submission offered by a Participant in the process of developing a Draft Standard or Final Standard for the purpose of incorporating such submission into a Final Standard, provided that such submission either (a) exists in a tangible form of expression (including in electronic media); or (b) is a verbal statement that is memorialized in written documentation (such as meeting minutes or a draft standard) and is either confirmed or not objected to by such Participant within fifteen (15) calendar days after its receipt of such memorialization. 2.4“Draft Standard” means any CDISC standard or specification developed by a CDISC Group, prior to adoption and publication as a Final Standard. 2.5“Final Standard” means any CDISC standard adopted and published by CDISC as a Final (production version) Standard. 2.6“Licensee’s Product(s)” means only those specific portions of products (software, tools, data formats, other products or combinations thereof), not the product as a whole, that implement and are compliant with the relevant Required Portions of a Final Standard. 2.7 “Member” means all classes of CDISC membership as set forth in CDISC documentation and their Affiliates, including Corporate Benefactors, Corporate Sponsors, Corporate Members and Associate Members. 2.8“Necessary Claims” means those claims in any patent or patent application in any jurisdiction in the world, excluding design patents and design registrations, that would necessarily be infringed by an implementation of those portions of a particular Final Standard within the scope of the CDISC Group charter in effect at the time such Final Standard was developed. A patent claim is “necessarily infringed” only when it is not possible to avoid infringing it because there is no commercially reasonable, non-infringing alternative for implementing the Required Portions of such Final Standard. Notwithstanding the foregoing, Necessary Claims do not include any claims: (i) that may be contained in the same patent as Necessary Claims but are not themselves Necessary Claims; (ii) that cover solely any portions of any product and any combinations thereof that are not required for compliance with the Final Standard; (iii) that cover any enabling technologies that may be necessary to make or use any product or portion thereof that complies with a Final Standard, but are not themselves expressly set forth in the Final Standard (e.g., semiconductor manufacturing technology, compiler technology, object oriented technology, operating system technology, computers, networks, connectivity protocols, or the like); (iv) that cover implementation examples or reference implementations in the text of a Final Standard; or (v) that cover the implementation of other published specifications/standards developed elsewhere and merely referred to in the body of a Final Standard.Since this definition of Necessary Claims focuses solely on Final Standards, not Draft Standards, for purposes of applying the disclosure obligations in Section 5 of this Policy, references to disclosures of Non-Contributed Necessary Claims “covering a Draft Standard” shall be understood to assume that the Draft Standard at issue would ultimately be adopted, without modification, as a Final Standard. 2.9 “Non-Contributed Necessary Claims” means those Necessary Claims that cover not a Participant’s own Contribution but either: (a) the Contribution of another party; or (b) material that is otherwise included in a Final Standard. 2.10 “Participant” means any party that: (1) formally joins a CDISC Group as a listedparticipant; or (2) makes a Contribution to a CDISC Group; or (3) attends one (1) or more meeting(s)/teleconference(s) of a CDISC Group (in person or by telephone) within a one-year period. Participants and other parties must sign (either in writing or electronically) the document attached to this Policy as Attachment A before formally joining, taking part in, or making a Contribution to each particular CDISC Group. Note: A Participant may be an individual acting in its own individual capacity or an organization, and may or may not be a CDISC Member organization or from a CDISC Member organization. If the Participant is an organization, the Participant may be represented in CDISC Groups by a Representative. 2.11“Representative” means an individual who is identified to CDISC as having authority to participate in CDISC or a CDISC Group on behalf of the Participant organization by which s/he is employed. The actions and statements of such individual(s) will be deemed to legally bind such Representative’s Participant organization and its affiliates. 2.12“Required Portion” means a portion of a Final Standard that is required for an implementation to comply with a Final Standard (also known as a “normative” or “mandatory” portion), but not including any elements that are required solely for conformance with any optional (i.e., “non-normative,” “non-mandatory”) portion(s) of a Final Standard; provided, however, that where a Final Standard contains a choice of two or more portions, and implementing any one of the portions is required to comply with the Final Standard (i.e., mutually exclusive required options), each such portion shall be deemed to be a Required Portion. 3 Compensation-free Patent License Commitment Each Participant agrees that, upon request and subject to Sections 5.1 and 8, it will grant, to all parties implementing a Final Standard developed by a CDISC Group in which it was a Participant, a nonexclusive, compensation-free (i.e., no royalty or other fee), nontransferable, non-sublicensable, worldwide, and otherwise reasonable and non-discriminatory license under such Participant’s Necessary Claims covering such Final Standard, solely to make, have made, use, import, offer to sell, sell, lease, and otherwise distribute and dispose of Licensee’s Products that implement such Final Standard; provided, however, that such commitment to license shall not apply to any Necessary Claims for which the Participant does not have the right to license without obligation of payment of royalties or other material consideration by such Participant to an unaffiliated third party. The commitment to license arising under this Section shall be effective as of the date the party was first deemed to be a Participant in the applicable CDISC Group. 4 Copyright Ownership and Licenses 4.1Copyright Ownership in Final Standards. CDISC shall own the copyright in Final Standards developed by CDISC, subject to the underlying copyright rights of the contributing Participants and other copyright owners. Any publication of a Final Standard shall contain an appropriate copyright notice in the name of CDISC. 4.2Copyright License for Contributions. Upon submitting a Contribution, each contributing Participant grants and agrees to grant (i) to each Participant a non-exclusive, worldwide, perpetual, nontransferable, compensation-free license under the Participant’s copyright rights in the Contribution to reproduce, publish, display, perform, distribute, and create derivative works of the Contribution, solely for the purpose of creating and promoting the Draft Standard and Final Standard for which such Contribution was submitted, and (ii) to CDISC a non-exclusive, worldwide, perpetual, irrevocable, compensation-free license to reproduce, publish, display, perform, distribute, and create derivative works of such Contribution (including any Draft Standard, Final Standard, or portion or derivative thereof incorporating the Contribution), and to freely sublicense such rights through multiple tiers, for the purpose of creating and promoting the Draft Standard and Final Standard and for other CDISC activities. Upon the adoption of a Final Standard, CDISC hereby grants and agrees to grant to all Participants and without limiting the generality of the licenses granted herein is also authorized to grant to other parties a nonexclusive, compensation-free, non-transferable, non-sublicensable, worldwide, perpetual, copyright license to reproduce, publish, display, perform, and distribute the Final Standard solely for the purpose of creating and distributing a Licensee’s Product(s) and any accompanying documentation. CDISC may also sublicense such copyright rights to reproduce, publish, display, perform, and distribute the Final Standard to another standard development organization solely for the purpose of adopting the same standard, subject to the relevant CDISC approval procedures, if any, for such further distribution by other organizations as may be established by the CDISC Board of Directors. All reproductions of a Draft Standard or Final Standard shall include all copyright notices, disclaimers, limitations of liability, and other such statements contained in the original. 5 Treatment of Non-Contributed Necessary Claims 5.1Review Period / Licensing Obligations for Non-Contributed Necessary Claims. To ensure that all Participants have the opportunity to review each proposed Draft Standard as a complete document for purposes of identifying Non-Contributed Necessary Claims, CDISC shall, at least thirty (30) calendar days prior to the finalization of the Draft Standard, notify all Participants via e-mail and post the Draft Standard on the CDISC website for open review. During the review period, each Participant in the CDISC Group that developed the Draft Standard under review (as well as others that choose to take part in such review) shall: (a) review the Draft Standard; (b) disclose, pursuant to Section 5.2, any of its Non-Contributed Necessary Claim(s) covering such Draft Standard that the Participant is not willing to license to all implementers of the resulting Final Standard under the compensation-free and otherwise reasonable and non-discriminatory commitment of Section 3; and (c) submit, prior to the end of the review period, a written licensing declaration for any Non-Contributed Necessary Claim disclosed under subclause (b) indicating whether the Participant will commit to license such disclosed claim(s) at least on reasonable and non-discriminatory (“RAND”) terms and conditions (note, Necessary Claims that cover one’s own Contributions must be licensed compensation-free pursuant to Section 3). If a Participant declares its intent under subclause (c) to license the disclosed Non-Contributed Necessary Claim on a RAND basis, it will have a RAND licensing obligation for such disclosed claim to all implementers of the Final Standard. If instead the Participant declares its intent under subclause (c) not to commit to at least RAND licensing for such disclosed claim and withdraws prior to the end of the review period, such Participant will have no licensing obligation for such disclosed claim. If, however, the Participant fails to comply with either of these two options, it will be deemed to have committed to the compensation-free and otherwise reasonable and non-discriminatory licensing obligation of Section 3 (“Default Licensing Obligation”) for such disclosed claim. Any other Non-Contributed Necessary Claims of such Participants that were not disclosed prior to the end of the review period shall also be subject to the Default Licensing Obligation. For the avoidance of doubt, the Default Licensing Obligation (which obligation actually arose under Section 3 and which the Participant failed to avoid by complying with the disclosure/licensing declaration and (if applicable) withdrawal provvisions of this Section) applies to all of a Partticipant’s undisclosed Non-Contributed Necessary Claims coveringg the Final Standard ultimately resulting from the Draft Standard under review, despite the lack of actual and personal knowledge thereof by any individual Representative who participates in such CDISC Group on behalf of such Participant. In the event that a Participant discloses its intention not to make at least a RAND licensing commitment for certain of its Non-Contributed Necessary Claims, the CDISC Group that developed the affected Draft Standard will, in consultation with the CDISC Board of Directors, determine how best to proceed, such as by attempting to develop a revised version of the Draft Standard that works around the potentially blocking patent claims. If, after the review period ends, a Draft Standard is substantially modified, a subsequent review period shall be conducted, under the terms of Section 5.1, before the revised Draft Standard is adopted and published as a Final Standard. 5.2Minimum Contents of Disclosure. With respect to Non-Contributed Necessary Claims in issued patents and published patent applications subject to disclosure under Section 5.1, a Participant must disclose, at a minimum, the identity of the patent rights holder and/or applicant and the patent number or application number. With respect to unpublished patent applications subject to disclosure under Section 5.1, a Participant must disclose, at a minimum, the existence of the application containing the asserted Non-Contributed Necessary Claim(s) and identify the portion(s) of the Draft Standard on which such asserted claim(s) read(s), but need not disclose identifying information (e.g., application number, application contents). Nothing herein precludes broader disclosure of unpublished patent applications on a voluntary basis or pursuant to a non-disclosure agreement. If any disclosed patent or patent application contains Necessary Claims which, if licensed, would require a payment of royalties or other material consideration to an unaffiliated third party, the Participant must also highlight this fact in its disclosure statement. Nothing in this Section or this Policy imposes any duty on any Representative or Participant to perform a patent search or other search of intellectual property portfolios. 6 CDISC Processes; Statement Regarding Patent Disclosures and Other Issues 6.1CDISC Records of Patent Disclosures / Licensing Declarations. The CDISC President shall promptly provide to the CDISC Board of Directors, in writing, the information contained in any patent disclosure. CDISC shall maintain a file, accessible by the public, which includes all patent disclosure statements and licensing declarations received for any Draft Standard or Final Standard. CDISC shall also provide such information to any party, upon request, in order to facilitate such party’s ability to seek and obtain all known patent licenses necessary to implement a Final Standard in a Licensee’s Product. 6.2CDISC Patent Disclaimers. After CDISC’s adoption of the CDISC IP Policy,all published Final Standards shall include the following disclaimers (or their equivalent):“It is possible that implementation of and compliance with this standard may require use of subject matter covered by patent rights. By publication of this standard, no position is taken with respect to the existence or validity of any claim or of any patent rights in connection therewith. CDISC, including the CDISC Board of Directors, shall not be responsible for identifying patent claims for which a license may be required in order to implement this standard or for conducting inquiries into the legal validity or scope of those patents or patent claims that are brought to its attention.”In addition, when CDISC receives from a patent rights holder a written licensing declaration indicating that a license will be required from such patent rights holder by implementers of a Final Standard, then such published Final Standard shall also add the following statement to the end of the above disclaimer:“Certain patent rights holders have filed a statement of willingness to grant a patent license to all implementers of this standard, consistent with the requirements of the CDISC Intellectual Property Policy. CDISC, including the CDISC Board of Directors, makes no representation as to the reasonableness of any terms or conditions of the license agreements offered by such patent rights holders, and all negotiations regarding such terms and conditions must take place between the individual parties outside the context of CDISC. Further information regarding those parties who have claimed patent rights in the standard and expressed their willingness to provide a license may be obtained from the CDISC President. The user should be aware, however, that it is also possible that other patent rights that have not been disclosed to CDISC may be implicated by implementation of or compliance with the standard.” 6.3CDISC Statements Regarding General Disclaimers, Limitation of Liability, and Copyright License to End Users. All published Final Standards shall also include statements of warranty, disclaimer, and limitation of liability statements substantially similar to those in Section 9.4 and Section 9.5, as well as a copyright notice to end users consistent with Section 1. 7 ConfidentialityAll Contributions and information disclosed as a part of CDISC activities shall be deemed non-confidential, and neither CDISC nor any Participant or Representative assumes any confidentiality obligations. 8 Withdrawal/Termination 8.1A Participant may withdraw from CDISC, or from any CDISC Group, at any time by sending a written notice to CDISC. Withdrawal shall be effective upon receipt of such written notice by CDISC. 8.2Effect of Withdrawal/Termination. Notwithstanding the Participant’s withdrawal or termination, and except (as applicable) as provided in Section 5.1 or Section 8.3, a Participant’s agreement to grant a license under Section 3 or Section 5.1 (as applicable) shall remain in full force and effect for: (1) Necessary Claims covering a Contribution made by the withdrawing/terminating Participant that is incorporated into a Final Standard to which such Contribution was offered (even if such Final Standard is adopted after such Participant’s withdrawal/termination); or (2) Non-Contributed Necessary Claims covering a Final Standard as such Final Standard (or the Draft Standard from which it arose) existed on the date of withdrawal/termination (even if such Final Standard is adopted after such Participant’s withdrawal/termination); and (3) Necessary Claims covering a Final Standard adopted by CDISC after the effective date of the Participant’s withdrawal/termination that: (i) are necessary for the later-adopted Final Standard to be backwards compatible with a prior Final Standard; and (ii) are used in a substantially similar manner, extent, and result as such Necessary Claims were used in such prior Final Standard for which the Participant is obligated to grant licenses. All rights and obligations of the withdrawn/terminated Participant other than those specifically referenced in this Section 8.2 or Section 3, 5.1, or 4.2 shall cease upon such withdrawal/termination. 9 General 9.1 No Other Licenses. Except for the rights expressly provided under this Policy, neither CDISC nor any Participant grants or receives, by implication, estoppel, or otherwise, any rights under any patents, copyrights, or other intellectual property rights. 9.2 No Software Code in Required Portions of Standards. Except for data interchange formats, no Draft Standard or Final Standard, and no Contribution, may include software code (i.e., source code or object code), except for code that will be used for illustrative purposes only and will not be deemed to be a Required Portion of a Draft Standard or Final Standard. 9.3 Representations and Warranties. Each Participant shall be deemed to represent, warrant, and covenant, at the time of a Contribution by such Participant (or by its Representative), that to the best of its knowledge and ability: (a) it holds or has the right to grant all relevant licenses to any of its Contributions in all jurisdictions or territories in which it holds relevant intellectual property rights; (b) there are no limits to the Participant’s ability to make the grants, acknowledgments, and agreements herein; and (c) the Contribution does not subject any Contribution, Draft Standard, Final Standard, or implementations thereof, in whole or in part, to licensing obligations with additional restrictions or requirements inconsistent with those set forth in this Policy, or that would require any such Contribution, Final Standard, or implementation, in whole or in part, to be either: (i) disclosed or distributed in source code form; (ii) licensed for the purpose of making derivative works (other than as set forth in Section 4.2); or (iii) distributed at no charge, except as set forth in Sections 3, 5.1, and 4.2. If a Participant has knowledge that a Contribution made by any Participant or any other party may subject any Contribution, Draft Standard, Final Standard, or implementation, in whole or in part, to one or more of the licensing obligations listed in Section 9.3, such Participant shall give prompt notice of the same to the CDISC President who shall promptly notify all Participants. 9.4 No Other Warranties/Disclaimers. ALL PARTICIPANTS ACKNOWLEDGE THAT, EXCEPT AS PROVIDED UNDER SECTION 9.3, ALL DRAFT STANDARDS AND FINAL STANDARDS, AND ALL CONTRIBUTIONS TO FINAL STANDARDS AND DRAFT STANDARDS, ARE PROVIDED “AS IS” WITH NO WARRANTIES WHATSOEVER, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, AND THE PARTICIPANTS, REPRESENTATIVES , THE CDISC PRESIDENT, THE CDISC BOARD OF DIRECTORS, AND CDISC EXPRESSLY DISCLAIM ANY WARRANTY OF MERCHANTABILITY, NONINFRINGEMENT, FITNESS FOR ANY PARTICULAR OR INTENDED PURPOSE, OR ANY OTHER WARRANTY OTHERWISE ARISING OUT OF ANY PROPOSAL, FINAL STANDARDS OR DRAFT STANDARDS, OR CONTRIBUTION. 9.5 Limitation of Liability . IN NO EVENT WILL CDISC OR ANY OF ITS CONSTITUENT PARTS (INCLUDING, BUT NOT LIMITED TO, THE CDISC BOARD OF DIRECTORS, THE CDISC PRESIDENT, CDISC STAFF, AND CDISC MEMBERS) BE LIABLE TO ANY OTHER PERSON OR ENTITY FOR ANY LOSS OF PROFITS, LOSS OF USE, DIRECT, INDIRECT, INCIDENTAL, CONSEQUENTIAL, OR SPECIAL DAMAGES, WHETHER UNDER CONTRACT, TORT, WARRANTY, OR OTHERWISE, ARISING IN ANY WAY OUT OF THIS POLICY OR ANY RELATED AGREEMENT, WHETHER OR NOT SUCH PARTY HAD ADVANCE NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. 9.6 Publicity. Each Participant consents to the public disclosure and use of its name for purposes of publicly promoting Final Standards, including the use in statements regarding the compliance of the Participant’s Licensee’s Products with a Final Standard, unless such Participant explicitly indicates in writing to the CDISC President such Participant’s refusal to consent to such public disclosure and use of its name. 9.7 Governing Law / Jurisdiction / Venue. This Policy shall be construed and controlled by the laws of the State of Delaware without giving effect to conflict-of-law principles. The parties agree that all disputes arising in any way out of this Policy will be heard exclusively in, and all parties irrevocably consent to jurisdiction and venue in, the state and Federal courts of the State of Delaware. 9.8 Complete Agreement. This Policy (including all documents referenced herein) sets forth the entire understanding between CDISC and its Members and Participants and Representatives regarding the treatment of patent, copyright, and related issues and supersedes all prior agreements, representations, and understandings related thereto. 10 AuthorizationThis document has been approved and is in effect on this date: Name CDISC Board of Directors Date 11 Change ControlThis Policy is the complete and exclusive statement of the Clinical Data Interchange Standards Consortium, Inc.’s (“CDISC”) Intellectual Property policy, consistent with the CDISC Bylaws. Once this Policy has been approved by the CDISC Board of Directors, it will apply to Members and other parties to the extent they are Participants in one or more CDISC Groups. Any future revisions to this Policy (or any document referenced herein) will become effective only upon approval of such revisions by the CDISC Board and only after: (a) CDISC notifies all Members and Participants in writing (such as by e-mail) of such revisions; (b) a clear and conspicuous link to the revised Policy, with the revisions highlighted, is posted on the home page of the CDISC website (currently http://www.cdisc.org/) for all existing Members/Participants and potential new Members/Participants to see; and (c) Participants are afforded at least thirty (30) calendar days from the date of receiving notice of such revisions to withdraw from CDISC or from particular CDISC Groups; provided, however, that ministerial changes to this Policy, such as proofreading corrections or formatting changes, may be executed by the CDISC Board and, upon CDISC Board approval, shall be immediately effective as to all existing and new Participants, so long as a revised version of the Policy containing such ministerial changes is posted on the home page of the CDISC website. Any Participant that withdraws from CDISC or from a CDISC Group prior to the end of this thirty (30)-day period will be subject to the version of the Policy that was in effect prior to the Board-approved revisions, in accordance with its terms and the withdrawal provisions of such version, but will not be subject to new or revised terms of the revised Policy. Any existing Participant that does not so withdraw prior to the end of this thirty (30)-day period will be deemed to have ratified and accepted the revised Policy in its entirety even without written agreement to such revised Policy by such Participant.

Link

https://www.cdisc.org/standards/foundational/sdtmig

Keywords

  1. 3/9/20 3/9/20 -
  2. 11/5/20 11/5/20 -
  3. 4/13/21 4/13/21 - Dr. rer. medic Philipp Neuhaus
  4. 6/18/21 6/18/21 - Sarah Riepenhausen
  5. 6/21/21 6/21/21 - Sarah Riepenhausen
  6. 9/20/21 9/20/21 -
  7. 9/27/21 9/27/21 -
Copyright Holder

CDISC

Uploaded on

June 21, 2021

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

CDISC SDTM

Observation Class: Special Purpose - Domain: Comments

  1. StudyEvent: ODM
    1. Observation Class: Special Purpose - Domain: Comments
    2. Observation Class: Special Purpose - Domain: Demographics
    3. Observation Class: Special Purpose - Domain: Subject Elements
    4. Observation Class: Special Purpose - Domain: Subject Disease Milestones
    5. Observation Class: Special Purpose - Domain: Subject Visits
    6. Observation Class: Interventions - Domain: Procedure Agents
    7. Observation Class: Interventions - Domain: Concomitant/Prior Medications
    8. Observation Class: Interventions - Domain: Exposure
    9. Observation Class: Interventions - Domain: Exposure as Collected
    10. Observation Class: Interventions - Domain: Meal Data
    11. Observation Class: Interventions - Domain: Procedures
    12. Observation Class: Interventions - Domain: Substance Use
    13. Observation Class: Events - Domain: Adverse Events
    14. Observation Class: Events - Domain: Clinical Events
    15. Observation Class: Events - Domain: Disposition
    16. Observation Class: Events - Domain: Protocol Deviations
    17. Observation Class: Events - Domain: Healthcare Encounters
    18. Observation Class: Events - Domain: Medical History
    19. Observation Class: Findings - Domain: Drug Accountability
    20. Observation Class: Findings - Domain: Death Details
    21. Observation Class: Findings - Domain: ECG Test Results
    22. Observation Class: Findings - Domain: Inclusion/Exclusion Criteria Not Met
    23. Observation Class: Findings - Domain: Immunogenicity Specimen Assessments
    24. Observation Class: Findings - Domain: Laboratory Test Results
    25. Observation Class: Findings - Domain: Microbiology Specimen
    26. Observation Class: Findings - Domain: Microbiology Susceptibility
    27. Observation Class: Findings - Domain: Microscopic Findings
    28. Observation Class: Findings - Domain: Morphology
    29. Observation Class: Findings - Domain: Cardiovascular System Findings
    30. Observation Class: Findings - Domain: Musculoskeletal System Findings
    31. Observation Class: Findings - Domain: Nervous System Findings
    32. Observation Class: Findings - Domain: Ophthalmic Examinations
    33. Observation Class: Findings - Domain: Reproductive System Findings
    34. Observation Class: Findings - Domain: Respiratory System Findings
    35. Observation Class: Findings - Domain: Urinary System Findings
    36. Observation Class: Findings - Domain: Pharmacokinetics Concentrations
    37. Observation Class: Findings - Domain: Pharmacokinetics Parameters
    38. Observation Class: Findings - Domain: Physical Examination
    39. Observation Class: Findings - Domain: Functional Tests
    40. Observation Class: Findings - Domain: Questionnaires
    41. Observation Class: Findings - Domain: Disease Response and Clin Classification
    42. Observation Class: Findings - Domain: Subject Characteristics
    43. Observation Class: Findings - Domain: Subject Status
    44. Observation Class: Findings - Domain: Tumor/Lesion Identification
    45. Observation Class: Findings - Domain: Tumor/Lesion Results
    46. Observation Class: Findings - Domain: Vital Signs
    47. Observation Class: Findings - Domain: Findings About Events or Interventions
    48. Observation Class: Findings - Domain: Skin Response
    49. Observation Class: Trial Design - Domain: Trial Arms
    50. Observation Class: Trial Design - Domain: Trial Elements
    51. Observation Class: Trial Design - Domain: Trial Visits
    52. Observation Class: Trial Design - Domain: Trial Disease Assessments
    53. Observation Class: Trial Design - Domain: Trial Disease Milestones
    54. Observation Class: Trial Design - Domain: Trial Inclusion/Exclusion Criteria
    55. Observation Class: Trial Design - Domain: Trial Summary Information
    56. Observation Class: Relationships - Domain: Related Records
    57. Observation Class: Relationships - Domain: Supplemental Qualifiers for [domain name]
    58. Observation Class: Relationships - Domain: Related Subjects
    59. Observation Class: Study Reference - Domain: Non-host Organism Identifiers
Comments
Description

Comments

Alias
SDTMIG v3.3
CO
NCIt V19.10d:
C49569
UMLS CUI-1
C1705247
Study Identifier
Description

Role: Identifier CDISC Notes (for domains) Description (for General Classes): Unique identifier for a study. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1]
C2826693
SDTMIG 3.3
STUDYID
NCIt V19.10d
C83082
Domain Abbreviation
Description

Role: Identifier CDISC Notes (for domains) Description (for General Classes): Two-character abbreviation for the domain. Controlled Terms or Format (if applicable): CO

Data type

text

Alias
UMLS CUI [1,1]
C1883204
UMLS CUI [1,2]
C0000723
SDTMIG 3.3
DOMAIN
NCIt V19.10d
C49556
Related Domain Abbreviation
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Two-character abbreviation for the domain of the parent record(s). Null for comments collected on a general comments or additional information CRF page. Controlled Terms or Format (if applicable): NA, extensible

Data type

text

Alias
UMLS CUI [1,1]
C1883204
UMLS CUI [1,2]
C0000723
SDTMIG 3.3
RDOMAIN
NCIt V19.10d
C83391
Unique Subject Identifier
Description

Role: Identifier CDISC Notes (for domains) Description (for General Classes): Identifier used to uniquely identify a subject across all studies for all applications or submissions involving the product. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C1710548
UMLS CUI [1,2]
C2826693
SDTMIG 3.3
USUBJID
NCIt V19.10d
C70731
Sequence Number
Description

Role: Identifier CDISC Notes (for domains) Description (for General Classes): Sequence Number given to ensure uniqueness of subject records within a domain. May be any valid number. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1]
C2348184
SDTMIG 3.3
COSEQ
NCIt V19.10d
C83240
Identifying Variable
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Identifying variable in the parent dataset that identifies the record(s) to which the comment applies. Examples AESEQ or CMGRPID. Used only when individual comments are related to domain records. Null for comments collected on separate CRFs. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C0600091
UMLS CUI [1,2]
C0439828
SDTMIG 3.3
IDVAR
NCIt V19.10d
C83293
Identifying Variable Value
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Value of identifying variable of the parent record(s). Used only when individual comments are related to domain records. Null for comments collected on separate CRFs. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C0600091
UMLS CUI [1,2]
C0439828
SDTMIG 3.3
IDVARVAL
NCIt V19.10d
C83294
Comment Reference
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Sponsor-defined reference associated with the comment. May be the CRF page number (e.g., 650), or a module name (e.g., DEMOG), or a combination of information that identifies the reference (e.g. 650-VITALS-VISIT 2). Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C0947611
UMLS CUI [1,2]
C1706462
SDTMIG 3.3
COREF
NCIt V19.10d
C82504
Comment
Description

Role: Topic CDISC Notes (for domains) Description (for General Classes): The text of the comment. Text over 200 characters can be added to additional columns COVAL1-COVALn. See Assumption 3. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1]
C0947611
SDTMIG 3.3
COVAL
NCIt V19.10d
C83241
Evaluator
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Used to describe the originator of the comment. Examples: CENTRAL, REVIEWER, ADJUDICATION COMMITTEE, PRINCIPAL INVESTIGATOR. Controlled Terms or Format (if applicable): NA

Data type

text

Alias
UMLS CUI [1,1]
C0947611
UMLS CUI [1,2]
C1707957
SDTMIG 3.3
COEVAL
NCIt V19.10d
C83239
Evaluator Identifier
Description

Role: Record Qualifier CDISC Notes (for domains) Description (for General Classes): Used to distinguish multiple evaluators with the same role recorded in --EVAL. Examples: RADIOLOGIST, RADIOLOGIST1, RADIOLOGIST2. Controlled Terms or Format (if applicable): (MEDEVAL), extensible

Data type

text

Alias
UMLS CUI [1,1]
C0947611
UMLS CUI [1,2]
C1707957
UMLS CUI [1,3]
C0600091
SDTMIG 3.3
COEVALID
NCIt V19.10d
C117043
NCIt V19.10d-2
C49569
Date/Time of Comment
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Date/time of comment on dedicated comment form. Should be null if this is a child record of another domain or if comment date was not collected. Controlled Terms or Format (if applicable): ISO 8601

Data type

datetime

Alias
UMLS CUI [1,1]
C1264639
UMLS CUI [1,2]
C0947611
SDTMIG 3.3
CODTC
NCIt V19.10d
C83238
Study Day of Comment
Description

Role: Timing CDISC Notes (for domains) Description (for General Classes): Study day of the comment, in integer days. The algorithm for calculations must be relative to the sponsor-defined RFSTDTC variable in the Demographics (DM) domain. Controlled Terms or Format (if applicable): NA

Data type

integer

Measurement units
  • d
Alias
UMLS CUI [1,1]
C0947611
UMLS CUI [1,2]
C2826182
SDTMIG 3.3
CODY
NCIt V19.10d
C119819
d

Similar models

Observation Class: Special Purpose - Domain: Comments

  1. StudyEvent: ODM
    1. Observation Class: Special Purpose - Domain: Comments
    2. Observation Class: Special Purpose - Domain: Demographics
    3. Observation Class: Special Purpose - Domain: Subject Elements
    4. Observation Class: Special Purpose - Domain: Subject Disease Milestones
    5. Observation Class: Special Purpose - Domain: Subject Visits
    6. Observation Class: Interventions - Domain: Procedure Agents
    7. Observation Class: Interventions - Domain: Concomitant/Prior Medications
    8. Observation Class: Interventions - Domain: Exposure
    9. Observation Class: Interventions - Domain: Exposure as Collected
    10. Observation Class: Interventions - Domain: Meal Data
    11. Observation Class: Interventions - Domain: Procedures
    12. Observation Class: Interventions - Domain: Substance Use
    13. Observation Class: Events - Domain: Adverse Events
    14. Observation Class: Events - Domain: Clinical Events
    15. Observation Class: Events - Domain: Disposition
    16. Observation Class: Events - Domain: Protocol Deviations
    17. Observation Class: Events - Domain: Healthcare Encounters
    18. Observation Class: Events - Domain: Medical History
    19. Observation Class: Findings - Domain: Drug Accountability
    20. Observation Class: Findings - Domain: Death Details
    21. Observation Class: Findings - Domain: ECG Test Results
    22. Observation Class: Findings - Domain: Inclusion/Exclusion Criteria Not Met
    23. Observation Class: Findings - Domain: Immunogenicity Specimen Assessments
    24. Observation Class: Findings - Domain: Laboratory Test Results
    25. Observation Class: Findings - Domain: Microbiology Specimen
    26. Observation Class: Findings - Domain: Microbiology Susceptibility
    27. Observation Class: Findings - Domain: Microscopic Findings
    28. Observation Class: Findings - Domain: Morphology
    29. Observation Class: Findings - Domain: Cardiovascular System Findings
    30. Observation Class: Findings - Domain: Musculoskeletal System Findings
    31. Observation Class: Findings - Domain: Nervous System Findings
    32. Observation Class: Findings - Domain: Ophthalmic Examinations
    33. Observation Class: Findings - Domain: Reproductive System Findings
    34. Observation Class: Findings - Domain: Respiratory System Findings
    35. Observation Class: Findings - Domain: Urinary System Findings
    36. Observation Class: Findings - Domain: Pharmacokinetics Concentrations
    37. Observation Class: Findings - Domain: Pharmacokinetics Parameters
    38. Observation Class: Findings - Domain: Physical Examination
    39. Observation Class: Findings - Domain: Functional Tests
    40. Observation Class: Findings - Domain: Questionnaires
    41. Observation Class: Findings - Domain: Disease Response and Clin Classification
    42. Observation Class: Findings - Domain: Subject Characteristics
    43. Observation Class: Findings - Domain: Subject Status
    44. Observation Class: Findings - Domain: Tumor/Lesion Identification
    45. Observation Class: Findings - Domain: Tumor/Lesion Results
    46. Observation Class: Findings - Domain: Vital Signs
    47. Observation Class: Findings - Domain: Findings About Events or Interventions
    48. Observation Class: Findings - Domain: Skin Response
    49. Observation Class: Trial Design - Domain: Trial Arms
    50. Observation Class: Trial Design - Domain: Trial Elements
    51. Observation Class: Trial Design - Domain: Trial Visits
    52. Observation Class: Trial Design - Domain: Trial Disease Assessments
    53. Observation Class: Trial Design - Domain: Trial Disease Milestones
    54. Observation Class: Trial Design - Domain: Trial Inclusion/Exclusion Criteria
    55. Observation Class: Trial Design - Domain: Trial Summary Information
    56. Observation Class: Relationships - Domain: Related Records
    57. Observation Class: Relationships - Domain: Supplemental Qualifiers for [domain name]
    58. Observation Class: Relationships - Domain: Related Subjects
    59. Observation Class: Study Reference - Domain: Non-host Organism Identifiers
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Comments
CO (SDTMIG v3.3)
C49569 (NCIt V19.10d:)
C1705247 (UMLS CUI-1)
STUDYID
Item
Study Identifier
text
C2826693 (UMLS CUI [1])
STUDYID (SDTMIG 3.3)
C83082 (NCIt V19.10d)
DOMAIN
Item
Domain Abbreviation
text
C1883204 (UMLS CUI [1,1])
C0000723 (UMLS CUI [1,2])
DOMAIN (SDTMIG 3.3)
C49556 (NCIt V19.10d)
Item
Related Domain Abbreviation
text
C1883204 (UMLS CUI [1,1])
C0000723 (UMLS CUI [1,2])
RDOMAIN (SDTMIG 3.3)
C83391 (NCIt V19.10d)
Code List
Related Domain Abbreviation
CL Item
Analysis Dataset (AD)
ADaM (Comment:en)
C1704642 (UMLS CUI-1)
C49563 (NCIt V19.10d)
CL Item
Adverse Events (AE)
C1705413 (UMLS CUI-1)
C49562 (NCIt V19.10d)
CL Item
Procedure Agents (AG)
C3888235 (UMLS CUI-1)
C117755 (NCIt V19.10d)
CL Item
Associated Persons Adverse Events (APAE)
SDTMIG-AP (Comment:en)
C4688600 (UMLS CUI-1)
C147168 (NCIt V19.10d)
CL Item
Associated Persons Biospecimen (APBS)
SDTMIG-AP (Comment:en)
C4687757 (UMLS CUI-1)
C147169 (NCIt V19.10d)
CL Item
Associated Persons Death Details (APDD)
SDTMIG-AP (Comment:en)
C4687758 (UMLS CUI-1)
C147170 (NCIt V19.10d)
CL Item
Associated Persons Demographics (APDM)
SDTMIG-AP (Comment:en)
C4329363 (UMLS CUI-1)
C132354 (NCIt V19.10d)
CL Item
Associated Persons Exposure (APEX)
SDTMIG-AP (Comment:en)
C4553046 (UMLS CUI-1)
C147171 (NCIt V19.10d)
CL Item
Associated Persons Laboratory Test Results (APLB)
SDTMIG-AP (Comment:en)
C4687759 (UMLS CUI-1)
C147172 (NCIt V19.10d)
CL Item
Associated Persons Medical History (APMH)
SDTMIG-AP (Comment:en)
C4687760 (UMLS CUI-1)
C147173 (NCIt V19.10d)
CL Item
Associated Persons Questionnaires (APQS)
SDTMIG-AP (Comment:en)
C4687761 (UMLS CUI-1)
C147174 (NCIt V19.10d)
CL Item
Relationship between Associated Persons and Subjects (APRELSUB)
SDTMIG-AP (Comment:en)
C4687762 (UMLS CUI-1)
C147175 (NCIt V19.10d)
CL Item
Associated Persons Reproductive System Findings (APRP)
SDTMIG-AP (Comment:en)
C4687763 (UMLS CUI-1)
C147176 (NCIt V19.10d)
CL Item
Associated Persons Subject Characteristics (APSC)
SDTMIG-AP (Comment:en)
C4553017 (UMLS CUI-1)
C147177 (NCIt V19.10d)
CL Item
Associated Persons Subject Status (APSS)
SDTMIG-AP (Comment:en)
C4553488 (UMLS CUI-1)
C147178 (NCIt V19.10d)
CL Item
Associated Persons Substance Use (APSU)
SDTMIG-AP (Comment:en)
C4687764 (UMLS CUI-1)
C147179 (NCIt V19.10d)
CL Item
Non-Compliant ADaM Dataset (AX)
ADaM (Comment:en)
C3714936 (UMLS CUI-1)
C111282 (NCIt V19.10d)
CL Item
Biospecimen Events (BE)
SDTMIG-PGx (Comment:en)
C3811654 (UMLS CUI-1)
C111138 (NCIt V19.10d)
CL Item
Biospecimen Findings (BS)
SDTMIG-PGx (Comment:en)
C3814390 (UMLS CUI-1)
C111137 (NCIt V19.10d)
CL Item
Clinical Events (CE)
C2827664 (UMLS CUI-1)
C85441 (NCIt V19.10d)
CL Item
Concomitant/Prior Medications (CM)
C1704627 (UMLS CUI-1)
C49568 (NCIt V19.10d)
CL Item
Comments (CO)
C1705247 (UMLS CUI-1)
C49569 (NCIt V19.10d)
CL Item
Cardiovascular System Findings (CV)
C3538987 (UMLS CUI-1)
C102605 (NCIt V19.10d)
CL Item
Drug Accountability (DA)
C1704643 (UMLS CUI-1)
C49578 (NCIt V19.10d)
CL Item
Death Details; Death Diagnosis and Details (DD)
C2986893 (UMLS CUI-1)
C95087 (NCIt V19.10d)
CL Item
Device Events (DE)
SDTMIG-MD (Comment:en)
C3541240 (UMLS CUI-1)
C102616 (NCIt V19.10d)
CL Item
Device Identifiers (DI)
SDTMIG-MD (Comment:en)
C3541881 (UMLS CUI-1)
C102618 (NCIt V19.10d)
CL Item
Demographics (DM)
C1704791 (UMLS CUI-1)
C49572 (NCIt V19.10d)
CL Item
Device Properties (DO)
SDTMIG-MD (Comment:en)
C3539061 (UMLS CUI-1)
C102619 (NCIt V19.10d)
CL Item
Device-Subject Relationships (DR)
SDTMIG-MD (Comment:en)
C3540849 (UMLS CUI-1)
C102620 (NCIt V19.10d)
CL Item
Disposition (DS)
C1705555 (UMLS CUI-1)
C49576 (NCIt V19.10d)
CL Item
Device Tracking and Disposition (DT)
SDTMIG-MD (Comment:en)
C3542920 (UMLS CUI-1)
C102621 (NCIt V19.10d)
CL Item
Device In-Use (DU)
SDTMIG-MD (Comment:en)
C3540681 (UMLS CUI-1)
C102622 (NCIt V19.10d)
CL Item
Protocol Deviations (DV)
C1704645 (UMLS CUI-1)
C49585 (NCIt V19.10d)
CL Item
Device Exposure (DX)
SDTMIG-MD (Comment:en)
C3538936 (UMLS CUI-1)
C102617 (NCIt V19.10d)
CL Item
Exposure as Collected (EC)
C3890233 (UMLS CUI-1)
C117466 (NCIt V19.10d)
CL Item
Endocrine System Findings (ED)
not defined in SDTMIG v3.3 (Comment:en)
C3538926 (UMLS CUI-1)
C102630 (NCIt V19.10d)
CL Item
ECG Test Results (EG)
C1705651 (UMLS CUI-1)
C49626 (NCIt V19.10d)
CL Item
Exposure (EX)
C1704625 (UMLS CUI-1)
C49587 (NCIt V19.10d)
CL Item
Findings About Events or Interventions (FA)
C2827665 (UMLS CUI-1)
C85442 (NCIt V19.10d)
CL Item
Functional Tests (FT)
C3890579 (UMLS CUI-1)
C117756 (NCIt V19.10d)
CL Item
Gastrointestinal System Findings (GI)
not defined in SDTMIG v3.3 (Comment:en)
C3539617 (UMLS CUI-1)
C102640 (NCIt V19.10d)
CL Item
Hematopoietic System Findings (HM)
not defined in SDTMIG v3.3 (Comment:en)
C3538713 (UMLS CUI-1)
C102641 (NCIt V19.10d)
CL Item
Healthcare Encounters (HO)
C3889614 (UMLS CUI-1)
C117757 (NCIt V19.10d)
CL Item
Inclusion/Exclusion Criteria Not Met (IE)
C1881173 (UMLS CUI-1)
C61536 (NCIt V19.10d)
CL Item
Immunogenicity Specimen Assessments (IS)
C3812801 (UMLS CUI-1)
C112320 (NCIt V19.10d)
CL Item
Laboratory Test Results (LB)
C1705214 (UMLS CUI-1)
C49592 (NCIt V19.10d)
CL Item
Microbiology Specimen (MB)
C1706181 (UMLS CUI-1)
C49602 (NCIt V19.10d)
CL Item
Medical History (MH)
C1704706 (UMLS CUI-1)
C49603 (NCIt V19.10d)
CL Item
Microscopic Findings (MI)
C2986901 (UMLS CUI-1)
C95095 (NCIt V19.10d)
CL Item
Musculoskeletal System Findings (MK)
C3539059 (UMLS CUI-1)
C102674 (NCIt V19.10d)
CL Item
Meal Data (ML)
C1706380 (UMLS CUI-1)
C49604 (NCIt V19.10d)
CL Item
Morphology (MO)
C3538743 (UMLS CUI-1)
C102671 (NCIt V19.10d)
CL Item
Microbiology Susceptibility (MS)
C1881819 (UMLS CUI-1)
C61531 (NCIt V19.10d)
CL Item
Nervous System Findings (NV)
C3540591 (UMLS CUI-1)
C102677 (NCIt V19.10d)
CL Item
Ophthalmic Examinations (OE)
C4552124 (UMLS CUI-1)
C147180 (NCIt V19.10d)
CL Item
Non-host Organism Identifiers (OI)
C5202881 (UMLS CUI-1)
C161329 (NCIt V19.10d)
CL Item
Pharmacogenomics Biomarker (PB)
SDTMIG-PGx (Comment:en)
C3819255 (UMLS CUI-1)
C106552 (NCIt V19.10d)
CL Item
Pharmacokinetics Concentrations (PC)
SDTMIG-PGx (Comment:en)
C1706367 (UMLS CUI-1)
C49606 (NCIt V19.10d)
CL Item
Physical Examination (PE)
C1744699 (UMLS CUI-1)
C49608 (NCIt V19.10d)
CL Item
Pharmacogenomics/Genetics Findings (PF)
SDTMIG-PGx (Comment:en)
C3815179 (UMLS CUI-1)
C111289 (NCIt V19.10d)
CL Item
Pharmacogenomics/Genetics Methods and Supporting Information (PG)
SDTMIG-PGx (Comment:en)
C1882354 (UMLS CUI-1)
C61529 (NCIt V19.10d)
CL Item
Pool Definition (POOLDEF)
SEND (Comment:en)
C4687765 (UMLS CUI-1)
C147181 (NCIt V19.10d)
CL Item
Pharmacokinetic Parameters (PP)
C1705911 (UMLS CUI-1)
C49607 (NCIt V19.10d)
CL Item
Procedures (PR)
C3538935 (UMLS CUI-1)
C102700 (NCIt V19.10d)
CL Item
Questionnaires (QS)
C1706422 (UMLS CUI-1)
C49609 (NCIt V19.10d)
CL Item
Respiratory System Findings (RE)
C2986904 (UMLS CUI-1)
C95098 (NCIt V19.10d)
CL Item
Related Records (RELREC)
C4687766 (UMLS CUI-1)
C147182 (NCIt V19.10d)
CL Item
Related Subjects (RELSUB)
C4552648 (UMLS CUI-1)
C147183 (NCIt V19.10d)
CL Item
Reproductive System Findings (RP)
C3541325 (UMLS CUI-1)
C102707 (NCIt V19.10d)
CL Item
Disease Response and Clin Classification (RS)
C3813325 (UMLS CUI-1)
C107097 (NCIt V19.10d)
CL Item
Subject Biomarker (SB)
SDTMIG-PGx (Comment:en)
C3811240 (UMLS CUI-1)
C106571 (NCIt V19.10d)
CL Item
Subject Characteristics (SC)
C1706465 (UMLS CUI-1)
C49610 (NCIt V19.10d)
CL Item
Subject Elements (SE)
C1705189 (UMLS CUI-1)
C49616 (NCIt V19.10d)
CL Item
Subject Disease Milestones (SM)
C4553627 (UMLS CUI-1)
C147184 (NCIt V19.10d)
CL Item
Skin Response (SR)
C3813610 (UMLS CUI-1)
C112420 (NCIt V19.10d)
CL Item
Subject Status (SS)
C3891295 (UMLS CUI-1)
C117655 (NCIt V19.10d)
CL Item
Substance Use (SU)
C1705534 (UMLS CUI-1)
C49615 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Adverse Events (SUPPAE)
C4687767 (UMLS CUI-1)
C147185 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Procedure Agents (SUPPAG)
C4687768 (UMLS CUI-1)
C147186 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Biospecimen Events (SUPPBE)
SDTMIG-PGx (Comment:en)
C4687769 (UMLS CUI-1)
C147187 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Biospecimen Findings (SUPPBS)
SDTMIG-PGx (Comment:en)
C4687770 (UMLS CUI-1)
C147189 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Clinical Events (SUPPCE)
C4687772 (UMLS CUI-1)
C147191 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Concomitant/Prior Medications (SUPPCM)
C4687774 (UMLS CUI-1)
C147193 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Cardiovascular System Findings (SUPPCV)
C4687776 (UMLS CUI-1)
C147195 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Drug Accountability (SUPPDA)
C4687777 (UMLS CUI-1)
C147196 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Death Details (human clinical trials) (SUPPDD)
C4687778 (UMLS CUI-1)
C147197 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Device Events (SUPPDE)
SDTMIG-MD (Comment:en)
C4687779 (UMLS CUI-1)
C147198 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Demographics (SUPPDM)
C4687781 (UMLS CUI-1)
C147200 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Device Properties (SUPPDO)
SDTMIG-MD (Comment:en)
C4687782 (UMLS CUI-1)
C147201 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Disposition (SUPPDS)
C4687784 (UMLS CUI-1)
C147203 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Device Tracking and Disposition (SUPPDT)
SDTMIG-MD (Comment:en)
C4687785 (UMLS CUI-1)
C147204 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Device In-Use (SUPPDU)
SDTMIG-MD (Comment:en)
C4687786 (UMLS CUI-1)
C147205 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Protocol Deviations (SUPPDV)
C4687787 (UMLS CUI-1)
C147206 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Device Exposure (SUPPDX)
SDTMIG-MD (Comment:en)
C4687788 (UMLS CUI-1)
C147207 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Exposure as Collected (SUPPEC)
C4687789 (UMLS CUI-1)
C147208 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for ECG Test Results (SUPPEG)
C4687790 (UMLS CUI-1)
C147209 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Environmental and Social Factors (SUPPER)
not defined in SDTMIG v3.3 (Comment:en)
C4554000 (UMLS CUI-1)
C147210 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Exposure (SUPPEX)
C4687791 (UMLS CUI-1)
C147211 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Findings About Events or Interventions (SUPPFA)
C4687792 (UMLS CUI-1)
C147212 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Healthcare Encounters (SUPPHO)
C4687796 (UMLS CUI-1)
C147216 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Inclusion/Exclusion Criteria Not Met (SUPPIE)
C4687798 (UMLS CUI-1)
C147218 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Immunogenicity Specimen Assessments (SUPPIS)
C4687799 (UMLS CUI-1)
C147219 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Laboratory Test Results (SUPPLB)
C4687800 (UMLS CUI-1)
C147220 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Microbiology Specimen (SUPPMB)
C4687802 (UMLS CUI-1)
C147222 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Medical History (SUPPMH)
C4687803 (UMLS CUI-1)
C147223 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Microscopic Findings (SUPPMI)
C4687804 (UMLS CUI-1)
C147224 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Musculoskeletal System Findings (SUPPMK)
C4687805 (UMLS CUI-1)
C147225 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Meal Data (SUPPML)
C4687806 (UMLS CUI-1)
C147226 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Microbiology Susceptibility (SUPPMS)
C4687807 (UMLS CUI-1)
C147227 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Nervous System Findings (SUPPNV)
C4687808 (UMLS CUI-1)
C147228 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Ophthalmic Examinations (SUPPOE)
C4687809 (UMLS CUI-1)
C147229 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Pharmacogenomics/Genetics Biomarker (SUPPPB)
SDTMIG-PGx (Comment:en)
C4687812 (UMLS CUI-1)
C147232 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Pharmacokinetics Concentrations (SUPPPC)
C4687813 (UMLS CUI-1)
C147233 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Physical Examination (SUPPPE)
C4687814 (UMLS CUI-1)
C147234 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Pharmacogenomics/Genetics Findings (SUPPPF)
SDTMIG-PGx (Comment:en)
C4687815 (UMLS CUI-1)
C147235 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Pharmacogenomics/Genetics Methods and Supporting Information (SUPPPG)
SDTMIG-PGx (Comment:en)
C4687816 (UMLS CUI-1)
C147236 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Pharmacokinetic Parameters (SUPPPP)
C4687818 (UMLS CUI-1)
C147238 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Procedures (SUPPPR)
C4687819 (UMLS CUI-1)
C147239 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Questionnaires (SUPPQS)
C4687820 (UMLS CUI-1)
C147240 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for ECG QT Correction Model Data (SUPPQT)
not defined in SDTMIG v3.3 (Comment:en)
C4687821 (UMLS CUI-1)
C147241 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Respiratory Test Results (SUPPRE)
C4687822 (UMLS CUI-1)
C147242 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Reproductive System Findings (SUPPRP)
C4687823 (UMLS CUI-1)
C147243 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Disease Response (SUPPRS)
C4687824 (UMLS CUI-1)
C147244 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Subject Biomarker (SUPPSB)
C4687825 (UMLS CUI-1)
C147245 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Subject Characteristics (SUPPSC)
C4687826 (UMLS CUI-1)
C147246 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Subject Disease Milestones (SUPPSM)
C4687829 (UMLS CUI-1)
C147249 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Skin Response (SUPPSR)
C4687830 (UMLS CUI-1)
C147250 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Subject Status (SUPPSS)
C4687831 (UMLS CUI-1)
C147251 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Substance Use (SUPPSU)
C4687832 (UMLS CUI-1)
C147252 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Tumor Response (SUPPTR)
C4687841 (UMLS CUI-1)
C147261 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Tumor/Lesion Identification (SUPPTU)
C4687844 (UMLS CUI-1)
C147264 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Urinary System Findings (SUPPUR)
C4687846 (UMLS CUI-1)
C147267 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Vital Signs (SUPPVS)
C4687847 (UMLS CUI-1)
C147268 (NCIt V19.10d)
CL Item
Supplemental Qualifiers for Whole Body Findings (SUPPWB)
not defined in SDTMIG v3.3 (Comment:en)
C4687848 (UMLS CUI-1)
C147269 (NCIt V19.10d)
CL Item
Subject Visits (SV)
C1704677 (UMLS CUI-1)
C49617 (NCIt V19.10d)
CL Item
Trial Arms (TA)
C1705538 (UMLS CUI-1)
C49618 (NCIt V19.10d)
CL Item
Trial Disease Assessments (TD)
C3889651 (UMLS CUI-1)
C117699 (NCIt V19.10d)
CL Item
Trial Elements (TE)
C1705540 (UMLS CUI-1)
C49619 (NCIt V19.10d)
CL Item
Trial Inclusion/Exclusion Criteria (TI)
C1704756 (UMLS CUI-1)
C49620 (NCIt V19.10d)
CL Item
Trial Disease Milestones (TM)
C4552802 (UMLS CUI-1)
C147270 (NCIt V19.10d)
CL Item
Tumor/Lesion Results (TR)
C3814152 (UMLS CUI-1)
C106578 (NCIt V19.10d)
CL Item
Trial Summary (TS)
C1704618 (UMLS CUI-1)
C53483 (NCIt V19.10d)
CL Item
Tumor/Lesion Identification (TU)
C3811255 (UMLS CUI-1)
C106577 (NCIt V19.10d)
CL Item
Trial Visits (TV)
C1704705 (UMLS CUI-1)
C49621 (NCIt V19.10d)
CL Item
Trial Sets (TX)
C2986909 (UMLS CUI-1)
C95103 (NCIt V19.10d)
CL Item
Urinary System Findings (UR)
C3541338 (UMLS CUI-1)
C102726 (NCIt V19.10d)
CL Item
Vital Signs (VS)
C1704629 (UMLS CUI-1)
C49622 (NCIt V19.10d)
USUBJID
Item
Unique Subject Identifier
text
C1710548 (UMLS CUI [1,1])
C2826693 (UMLS CUI [1,2])
USUBJID (SDTMIG 3.3)
C70731 (NCIt V19.10d)
SEQ
Item
Sequence Number
text
C2348184 (UMLS CUI [1])
COSEQ (SDTMIG 3.3)
C83240 (NCIt V19.10d)
IDVAR
Item
Identifying Variable
text
C0600091 (UMLS CUI [1,1])
C0439828 (UMLS CUI [1,2])
IDVAR (SDTMIG 3.3)
C83293 (NCIt V19.10d)
IDVARVAL
Item
Identifying Variable Value
text
C0600091 (UMLS CUI [1,1])
C0439828 (UMLS CUI [1,2])
IDVARVAL (SDTMIG 3.3)
C83294 (NCIt V19.10d)
REF
Item
Comment Reference
text
C0947611 (UMLS CUI [1,1])
C1706462 (UMLS CUI [1,2])
COREF (SDTMIG 3.3)
C82504 (NCIt V19.10d)
VAL
Item
Comment
text
C0947611 (UMLS CUI [1])
COVAL (SDTMIG 3.3)
C83241 (NCIt V19.10d)
EVAL
Item
Evaluator
text
C0947611 (UMLS CUI [1,1])
C1707957 (UMLS CUI [1,2])
COEVAL (SDTMIG 3.3)
C83239 (NCIt V19.10d)
Item
Evaluator Identifier
text
C0947611 (UMLS CUI [1,1])
C1707957 (UMLS CUI [1,2])
C0600091 (UMLS CUI [1,3])
COEVALID (SDTMIG 3.3)
C117043 (NCIt V19.10d)
C49569 (NCIt V19.10d-2)
Code List
Evaluator Identifier
CL Item
ADJUDICATOR (ADJUDICATOR)
C0401783 (UMLS CUI-1)
C96561 (NCIt V19.10d)
CL Item
ADJUDICATOR 1 (ADJUDICATOR 1)
C4726039 (UMLS CUI-1)
C150867 (NCIt V19.10d)
CL Item
ADJUDICATOR 2 (ADJUDICATOR 2)
C4726040 (UMLS CUI-1)
C150868 (NCIt V19.10d)
CL Item
ADJUDICATOR 3 (ADJUDICATOR 3)
C4726041 (UMLS CUI-1)
C150869 (NCIt V19.10d)
CL Item
CARDIOLOGIST (CARDIOLOGIST)
C0175906 (UMLS CUI-1)
C125951 (NCIt V19.10d)
CL Item
CLINICAL PATHOLOGIST (CLINICAL PATHOLOGIST)
C0334901 (UMLS CUI-1)
C142332 (NCIt V19.10d)
CL Item
DERMATOLOGIST (DERMATOLOGIST)
C0259831 (UMLS CUI-1)
C17816 (NCIt V19.10d)
CL Item
DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN (DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN)
C4687932 (UMLS CUI-1)
C147461 (NCIt V19.10d)
CL Item
DEVELOPMENTAL PSYCHOLOGIST (DEVELOPMENTAL PSYCHOLOGIST)
C4688605 (UMLS CUI-1)
C147462 (NCIt V19.10d)
CL Item
FORENSIC PATHOLOGIST (FORENSIC PATHOLOGIST)
C4684530 (UMLS CUI-1)
C142333 (NCIt V19.10d)
CL Item
HEMATOLOGIST (HEMATOLOGIST)
C0278598 (UMLS CUI-1)
C17831 (NCIt V19.10d)
CL Item
MICROSCOPIST (MICROSCOPIST)
C4330683 (UMLS CUI-1)
C132303 (NCIt V19.10d)
CL Item
MICROSCOPIST 1 (MICROSCOPIST 1)
C4330680 (UMLS CUI-1)
C132421 (NCIt V19.10d)
CL Item
MICROSCOPIST 2 (MICROSCOPIST 2)
C4330681 (UMLS CUI-1)
C132422 (NCIt V19.10d)
CL Item
MICROSCOPIST 3 (MICROSCOPIST 3)
C4330682 (UMLS CUI-1)
C132423 (NCIt V19.10d)
CL Item
NEUROLOGIST (NEUROLOGIST)
C0237426 (UMLS CUI-1)
C17721 (NCIt V19.10d)
CL Item
NEUROLOGIST 1 (NEUROLOGIST 1)
C3272968 (UMLS CUI-1)
C96692 (NCIt V19.10d)
CL Item
NEUROLOGIST 2 (NEUROLOGIST 2)
C3272896 (UMLS CUI-1)
C96606 (NCIt V19.10d)
CL Item
ONCOLOGIST (ONCOLOGIST)
C0259990 (UMLS CUI-1)
C17821 (NCIt V19.10d)
CL Item
ONCOLOGIST 1 (ONCOLOGIST 1)
C3272901 (UMLS CUI-1)
C96611 (NCIt V19.10d)
CL Item
ONCOLOGIST 2 (ONCOLOGIST 2)
C3272902 (UMLS CUI-1)
C96612 (NCIt V19.10d)
CL Item
OPHTHALMOLOGIST (OPHTHALMOLOGIST)
C1704292 (UMLS CUI-1)
C17822 (NCIt V19.10d)
CL Item
OPTOMETRIST (OPTOMETRIST)
C0029146 (UMLS CUI-1)
C132424 (NCIt V19.10d)
CL Item
PATHOLOGIST (PATHOLOGIST)
C0334866 (UMLS CUI-1)
C17723 (NCIt V19.10d)
CL Item
PATHOLOGIST 1 (PATHOLOGIST 1)
C4743735 (UMLS CUI-1)
C154836 (NCIt V19.10d)
CL Item
PATHOLOGIST 2 (PATHOLOGIST 2)
C4743736 (UMLS CUI-1)
C154837 (NCIt V19.10d)
CL Item
PEDIATRIC NEUROLOGIST (PEDIATRIC NEUROLOGIST)
C0586846 (UMLS CUI-1)
C147463 (NCIt V19.10d)
CL Item
Physical Therapist (PHYSIOTHERAPIST)
C2362565 (UMLS CUI-1)
C53422 (NCIt V19.10d)
CL Item
RADIOLOGIST (RADIOLOGIST)
C0260194 (UMLS CUI-1)
C17824 (NCIt V19.10d)
CL Item
RADIOLOGIST 1 (RADIOLOGIST 1)
C2986554 (UMLS CUI-1)
C94530 (NCIt V19.10d)
CL Item
RADIOLOGIST 2 (RADIOLOGIST 2)
C2986555 (UMLS CUI-1)
C94531 (NCIt V19.10d)
CL Item
RATER (RATER)
C4331219 (UMLS CUI-1)
C132304 (NCIt V19.10d)
CL Item
RATER 1 (RATER 1)
C4331218 (UMLS CUI-1)
C132425 (NCIt V19.10d)
CL Item
RATER 2 (RATER 2)
C4331939 (UMLS CUI-1)
C132426 (NCIt V19.10d)
CL Item
READER (READER)
C1514743 (UMLS CUI-1)
C28747 (NCIt V19.10d)
CL Item
READER 1 (READER 1)
C2986556 (UMLS CUI-1)
C94532 (NCIt V19.10d)
CL Item
READER 2 (READER 2)
C2986557 (UMLS CUI-1)
C94533 (NCIt V19.10d)
CL Item
READER 3 (READER 3)
C4528333 (UMLS CUI-1)
C139209 (NCIt V19.10d)
CL Item
UROLOGIST (UROLOGIST)
C0260314 (UMLS CUI-1)
C17826 (NCIt V19.10d)
DTC
Item
Date/Time of Comment
datetime
C1264639 (UMLS CUI [1,1])
C0947611 (UMLS CUI [1,2])
CODTC (SDTMIG 3.3)
C83238 (NCIt V19.10d)
DY
Item
Study Day of Comment
integer
C0947611 (UMLS CUI [1,1])
C2826182 (UMLS CUI [1,2])
CODY (SDTMIG 3.3)
C119819 (NCIt V19.10d)

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial